NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)
40.44
+1.13 (2.87%)
NASDAQ · Last Trade: Nov 26th, 1:05 AM EST
Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter
Via The Motley Fool · November 20, 2025
Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way
Via The Motley Fool · November 20, 2025
Bain Capital sold its entire stake in Nuvalent stock during the third quarter.
Via The Motley Fool · November 19, 2025

Via Benzinga · January 24, 2025
Bain Capital completely exited its position in Disc Medicine stock during the third quarter
Via The Motley Fool · November 19, 2025
Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.
Via The Motley Fool · November 18, 2025
Via Benzinga · October 20, 2025
Via Benzinga · August 25, 2025
Via Benzinga · August 7, 2025
Via Benzinga · June 12, 2025
NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation.
Via Benzinga · June 9, 2025
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · June 9, 2025
Via Benzinga · April 22, 2025
Via Benzinga · April 8, 2025
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.
Via Investor's Business Daily · March 31, 2025

Via Benzinga · February 26, 2025

Via Benzinga · February 26, 2025

Via Benzinga · January 16, 2025

These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN.
Via Benzinga · December 15, 2024

NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.
Via Investor's Business Daily · December 11, 2024

Via Benzinga · December 11, 2024

The results bode well for an ongoing Phase 3 study examining cardiovascular outcomes.
Via Investor's Business Daily · December 10, 2024


